Opponents, Drugmaker File Brief to Block Trump Hemp CBD Medicare Plan

Opponents and a drugmaker go to court

A brief filed by marijuana opponents and a pharmaceutical company asks a court to stop the Trump administration's hemp CBD Medicare coverage plan, according to Marijuana Moment on Oct. 6, 2026.

The headline and summary available to CannIntel don't identify the court, the docket number or the company. We'll add those details once the filing itself is verified.

Unlikely allies, one target

The challengers pair groups that oppose marijuana legalization with a commercial drug developer, two camps that likely have different motives.

A drugmaker's stake in a federal coverage program is commercial by definition. Medicare coverage rules decide which products get reimbursed and which don't.

The brief's specific arguments haven't been confirmed. Not yet.

The statutes that frame the fight

Two federal statutes anchor any dispute over hemp CBD in Medicare: the hemp definition at 7 U.S.C. § 1639o and Medicare's coverage standard at 42 U.S.C. § 1395y(a)(1)(A).

The first defines hemp as cannabis containing no more than 0.3% delta-9 THC on a dry-weight basis. The second bars Medicare payment for items that aren't "reasonable and necessary" for diagnosing or treating illness.

Whether the brief rests on those provisions, on FDA drug-approval law or on administrative-procedure grounds is the question that will define the case.

CannIntel hasn't verified which theories the filing advances.

What it means for hemp operators

An injunction would stall what would be the first federal payer channel for hemp-derived CBD, a prize processors and brands haven't been offered before.

Coverage would move CBD from cash-pay wellness shelves toward reimbursed medical use. That shift would raise the bar on product testing, labeling and claims, and it would pull in FDA and DEA oversight questions that hemp sellers have mostly sidestepped.

That's a prize worth litigating over. The filing isn't a surprise.

What we don't know yet

The court, the pharmaceutical company's identity, the relief requested and the government's response all remain unconfirmed.

Any ruling would also hinge on whether the challengers can show legal standing to contest a federal coverage decision. That threshold question sinks many policy challenges before the merits. For full background on this story, see the CannIntel topic hub on hemp CBD Medicare coverage.

The next signal: the government's response brief and any scheduling order on a preliminary injunction. CannIntel will update this story when the docket is confirmed.